Momenta Pharmaceuticals Now Covered by R. F. Lafferty (MNTA)
Stock analysts at R. F. Lafferty assumed coverage on shares of Momenta Pharmaceuticals (NASDAQ:MNTA) in a report issued on Monday, American Banking & Market News reports. The firm set a “buy” rating and a $19.00 price target on the stock. R. F. Lafferty’s price objective would suggest a potential upside of 21.17% from the stock’s previous close.
MNTA has been the subject of a number of other recent research reports. Analysts at TheStreet upgraded shares of Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note to investors on Wednesday, October 9th. Separately, analysts at Canaccord Genuity raised their price target on shares of Momenta Pharmaceuticals from $13.00 to $22.00 in a research note to investors on Monday, July 29th. Finally, analysts at Canaccord Genuity upgraded shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a research note to investors on Friday, July 26th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $18.17.
Shares of Momenta Pharmaceuticals (NASDAQ:MNTA) traded down 0.70% on Monday, hitting $15.57. 92,081 shares of the company’s stock traded hands. Momenta Pharmaceuticals has a 52-week low of $10.05 and a 52-week high of $18.08. The stock’s 50-day moving average is $15.03 and its 200-day moving average is $14.29. The company’s market cap is $791.2 million.
Momenta Pharmaceuticals (NASDAQ:MNTA) last released its earnings data on Thursday, August 1st. The company reported ($0.57) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.45) by $0.12. The company had revenue of $4.40 million for the quarter, compared to the consensus estimate of $8.85 million. During the same quarter last year, the company posted ($0.20) earnings per share. Momenta Pharmaceuticals’s revenue was down 79.9% compared to the same quarter last year. On average, analysts predict that Momenta Pharmaceuticals will post $-2.01 earnings per share for the current fiscal year.
Momenta Pharmaceuticals, Inc (NASDAQ:MNTA) is a biotechnology company specializing in the characterization and process engineering of complex molecules.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.